Risperdal Settlement Shows False Claims Act Prosecutions Still Have Teeth After Caronia
This article was originally published in RPM Report
A $2.2 billion settlement prompts another round of headlines about the pharmaceutical industry's marketing practices -- and no apparent indication that the Caronia ruling is changing the way prosecutors (and the public) perceive off-label promotion.
You may also be interested in...
A December appellate court ruling in an off-label promotion case prompted headlines about sweeping implications for FDA’s regulatory authority. How does the ruling look four months later?
GlaxoSmithKline pleads guilty to marketing Paxil and Wellbutrin off-label and concealing Avandia safety data from FDA and resolves allegations of kickbacks involving nine drugs; ground-breaking corporate integrity agreement includes novel recoup of bonuses from execs if they or their subordinates engage in “significant misconduct.”
Record setting $2.3 billion payment is afterthought in context of Pfizer/Wyeth merger, but the Bextra and recent Zyprexa settlement will have far-reaching implications. In economic terms, the first two cases of 2009 exceed the total recoveries of the last 13 pharma marketing settlements. But the big impact may be political: the cases involve a volatile mix of marketing abuses and drug safety